March 3, 2020 / 11:20 PM / a month ago

BRIEF-Acadia Pharmaceuticals And Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation For Trofinetide

March 3 (Reuters) - Neuren Pharmaceuticals:

* ACADIA PHARMACEUTICALS AND NEUREN PHARMACEUTICALS ANNOUNCE RARE PEDIATRIC DISEASE DESIGNATION FOR TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME

* NEUREN PHARMACEUTICALS - RESULTS FROM PHASE 3 LAVENDER STUDY EXPECTED IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below